Abstract
It has been estimated that >95% of cases of colorectal cancer (CRC) would benefit from curative surgery if diagnosis was made at an early or premalignant polyp stage of disease. Over the past 10 years, most developed nation states have implemented mass population screening programs, which are typically targeted at the older (at-risk) age group (>50–60 years old). Conventional screening largely relies on periodic patient-centric investigation, particularly involving colonoscopy and flexible sigmoidoscopy, or else on the fecal occult blood test. These methods are compromised by either low cost-effectiveness or limited diagnostic accuracy. Advances in the development of diagnostic molecular markers for CRC have yielded an expanding list of potential new screening modalities based on investigations of patient stool (for colonocyte DNA mutations, epigenetic changes or microRNA expression) or blood specimens (for plasma DNA mutations, epigenetic changes, heteroplasmic mitochondrial DNA mutations, leukocyte transcriptome profile, plasma microRNA expression or protein and autoantibody expression). In this Review, we present a critical evaluation of the performance data and relative merits of these various new potential methods. None of these molecular diagnostic methods have yet been evaluated beyond the proof-of-principle and pilot-scale study stage and it could be some years before they replace existing methods for population screening in CRC.
Key Points
-
Approximately 1 million new cases of colorectal cancer are diagnosed each year
-
Population screening for detection of disease at an early stage has demonstrated a significant reduction in mortality
-
The fecal occult blood test is the most widely adopted screening method, but is compromised by poor reliability and patient compliance
-
Although flexible sigmoidoscopy is cost-effective, more definitive direct investigative procedures (such as colonoscopy) are prohibitively expensive for most national screening programs
-
An expanding list of potential new screening methods based on the detection of DNA, RNA or protein molecular markers in patient stool or blood specimens is currently being evaluated
-
The introduction of screening based on molecular markers is likely to be an incremental process; established screening modalities are likely to remain in widespread use for some years
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Weitz, J. et al. Colorectal cancer. Lancet 365, 153–165 (2005).
Cancer Research UK. Bowel cancer statistics—UK. Cancer Research UK [online], (2011).
Kim, H. J., Yu, M. H., Kim, H., Byun, J. & Lee, C. Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep. 41, 685–692 (2008).
Verdecchia, A. et al. Recent cancer survival in Europe: a 2000–2002 period analysis of EUROCARE-4data. Lancet Oncol. 8, 784–796 (2007).
Gupta, A. K., Brenner, D. E. & Turgeon, D. K. Early detection of colon cancer: new tests on the horizon. Mol. Diag. Ther. 12, 77–85 (2008).
Burt, R. W. Colorectal cancer screening. Curr. Opin. Gastroenterol. 26, 466–470 (2010).
Hofstad, B. in Colonoscopy: Principles and Practice 1st edn (eds Waye, J. D., Rex, D. K., Williams, C. B.) 358–376 (Wiley-Blackwell, Oxford, 2003).
Ahlquist, D. A. Molecular detection of colorectal neoplasia. Gastroenterology 138, 2127–2139 (2010).
Lieberman, D. Progress and challenges in colorectal cancer screening and surveillance. Gastroenterology 138, 2115–2126 (2010).
Regula, J. et al. Colonoscopy in colorectal cancer screening for detection of advanced neoplasia. N. Engl. J. Med. 355, 1863–1872 (2006).
Kahi, C. J., Imperiale, T. F., Juliar, B. E. & Rex, D. K. Effect of screening colonoscopy on colorectal cancer incidence and mortality. Clin. Gastroenterol. Hepatol. 7, 770–775 (2009).
Rabeneck, L., Paszat, L. F., Saskin, R. & Stukel, T. A. Association between colonoscopy rates and colorectal cancer mortality. Am. J. Gastroenterol. 105, 1627–1632 (2010).
Baxter, N. N. et al. Association of colonoscopy and death from colorectal cancer. Ann. Intern. Med. 150, 1–8 (2009).
Brenner, H. et al. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J. Natl Cancer Inst. 102, 89–95 (2010).
The Northern-European Initiative on Colorectal Cancer (NordICC). ClinicalTrials.gov [online], (2011).
Nelson, S. R. & Thorson, A. G. Colorectal cancer screening. Curr. Oncol. Rep. 11, 482–489 (2009).
Ransohoff, A. F. How much does colonoscopy reduce colon cancer mortality? Ann. Intern. Med. 150, 50–52 (2009).
Ward, N., Wright, J., Marsh, S. & Norton, J. Fast track referrals for colorectal cancer: impact of the faecal occult blood test screening programme. Colorectal Dis. 9, 258–261 (2007).
Glick, S., Wagner, J. L. & Johnson, C. D. Cost-effectiveness of double contrast barium enema in screening for colorectal cancer. AJR Am. J. Roentgenol. 170, 629–636 (1998).
Toma, J., Paszat, L. F., Gunraj, N. & Rabeneck, L. Rates of new or missed colorectal cancer after barium enema and their risk factors: a population based study. Am. J. Gastroenterol. 103, 3142–3148 (2008).
Sosna, J. et al. CT colonography of colorectal polyps: a metaanalysis. AJR Am. J. Roentgenol. 181, 1593–1598 (2003).
Rosman, A. S. & Korsten, M. A. Meta-analysis comparing CT colonography, air contrast barium enema, and colonoscopy. Am. J. Med. 120, 203–210 (2007).
Vu, H. T. & Burke, C. A. Advances in colorectal cancer screening. Curr. Gastroenterol. Rep. 11, 406–412 (2009).
Knudsen, A. B. et al. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J. Natl Cancer Inst. 102, 1238–1252 (2010).
Sweet, A. et al. The impact of CT colonography for colorectal cancer screening on the UK NHS: costs, healthcare resources and health outcomes. Appl. Health Econ. Health Policy 9, 51–64 (2011).
Hoff, G., Grotmol, T., Skovlund, E. & Bretthauer, M. & Norwegian Colorectal Cancer Prevention Study Group. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 338, b1846 (2009).
Atkin, W. S. et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375, 1624–1633 (2010).
Segnan, N. et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian randomized controlled trial—SCORE. J. Natl Cancer Inst. 103, 1310–1322 (2011).
Tappenden, P. et al. Option appraisal of population-based colorectal cancer screening programmes in England. Gut 56, 677–684 (2007).
Towler, B. et al. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ 317, 559–565 (1998).
Zavoral, M. et al. Colorectal cancer screening in Europe. World J. Gastroenterol. 15, 5907–5915 (2009).
West, N. J., Boustiere, C., Fischbach, W., Parente, F. & Leicester, R. Colorectal cancer screening in Europe: differences in approach; similar barriers to overcome. Int. J. Colorectal Dis. 24, 731–740 (2009).
Vilkin, A. et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am. J. Gastroenterol. 100, 2519–2525 (2005).
Grazzini, G. et al. Influence of seasonal variations in ambient temperature on performance of immunochemical faecal occult blood test for colorectal cancer: observational study from the Florence district. Gut 59, 1511–1515 (2010).
Guittet, L. et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 56, 210–214 (2007).
Van Rossum, L. G. et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135, 82–90 (2008).
Parra-Blanco, A. et al. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer. J. Gastroenterol. 45, 703–712 (2010).
Li, S. et al. New immunochemical fecal occult blood test with two-consecutive stool sample testing is a cost-effective approach for colon cancer screening: results of a prospective multicenter study in Chinese patients. Int. J. Cancer 118, 3078–3083 (2006).
Parekh, M., Fendrick, A. M. & Ladabaum, U. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment. Pharmacol. Ther. 27, 697–712 (2008).
Zheng, S. et al. Cluster randomization trial of sequence mass screening for colorectal cancer. Dis. Colon Rectum 46, 51–58 (2003).
Potack, J. & Itzkowitz, S. H. Practical advances in stool screening for colorectal cancer. J. Natl Comp. Canc. Netw. 8, 81–92 (2010).
Imperiale, T. F. et al. Fecal DNA versus fecal occult blood for colorectal cancer screening in an average risk population. N. Engl. J. Med. 351, 2704–2714 (2004).
Ahlquist, D. A. et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann. Intern. Med. 149, 441–450 (2008).
Goel, A. DNA methylation-based fecal biomarkers for non-invasive screening of GI cancers. Future Oncol. 6, 333–336 (2010).
Song, K., Fendrick, A. M. & Ladabaum, U. Fecal DNA testing compared with conventional colorectal cancer screening methods: a decision analysis. Gastroenterology 126, 1270–1279 (2004).
Itzkowitz, S. et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am. J. Gastroenterol. 103, 2862–2870 (2008).
Paterlini-Brechot, P. & Benali, N. L. Circulating tumor cells (CTC): detection, clinical impact and future directions. Cancer Lett. 253, 180–204 (2007).
Sleijfer, S. et al. Circulating tumour cell detection on its way to routine diagnostic implementation. Eur. J. Cancer 43, 2645–2650 (2007).
Pantel, K., Brakenhoff, R. H. & Brandt, B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer 8, 329–340 (2008).
Sastre, J. et al. Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables. Ann. Oncol. 19, 935–938 (2008).
Wong, S. C. et al. Clinical significance of cytokeratin 20-positive circulating tumor cells detected by a refined immunomagnetic enrichment assay in colorectal cancer patients. Clin. Cancer Res. 15, 1005–1012 (2009).
Negin, B. P. & Cohen, S. J. Circulating tumor cells in colorectal cancer: past, present and future challenges. Curr. Treat. Options Oncol. 11, 1–13 (2010).
Allen, J. E. & El-Deiry, W. S. Circulating tumor cells and colorectal cancer. Curr. Colorectal Cancer Rep. 6, 212–220 (2010).
Cohen, S. J. et al. Relationship of circulating tumor cells to tumor response, progression-free survival and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 26, 3213–3221 (2008).
Tol, J. et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann. Oncol. 21, 1006–1012 (2010).
Antolovic, D. et al. Heterogenous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies. BMC Biotechnol. 10, 35 (2010).
Krivacic, R. T. et al. A rare-cell detector for cancer. Proc. Natl Acad. Sci. USA 101, 10501–10504 (2004).
Kraeft, S. K. et al. Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system. Clin. Cancer Res. 10, 3020–3028 (2004).
Marrinucci, D. et al. Cytomorphology of circulating colorectal tumor cells: a small case series. J. Oncol. 861341 (2010).
Nagrath, S. et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235–1239 (2007).
Stott, S. L. et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci. Transl. Med. 2, 25ra23 (2010).
Huerta, S. Recent advances in the molecular diagnosis and prognosis of colorectal cancer. Expert Rev. Mol. Diagn. 8, 277–288 (2008).
Wanebo, H. J. et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N. Engl. J. Med. 299, 448–451 (1978).
Posner, M. R. & Mayer, R. J. The use of serologic tumor markers in gastrointestinal malignancies. Hematol. Oncol. Clin. North Am. 8, 533–553 (1994).
Fletcher, R. H. Carcinoembryonic antigen. Ann. Intern. Med. 104, 66–73 (1986).
Hundt, S., Haug, U. & Brenner, H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol. Biomarkers Prev. 16, 1935–1953 (2007).
Tjalsma, H. Identification of biomarkers for colorectal cancer through proteomics-based approaches. Expert Rev. Proteomics 7, 879–895 (2010).
Leman, E. S. et al. Initial analysis of colon cancer-specific antigen CCSA-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res. 67, 5600–5605 (2007).
Walgenbach-Brunagel, G. et al. The use of a colon cancer associated nuclear antigen CCSA-2 for the blood-based detection of colon cancer. J. Cell. Biochem. 104, 286–294 (2008).
Hurst, N. G. et al. Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal cancer in symptomatic patients. Br. J. Cancer 97, 971–977 (2007).
Kim, H. J. et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J. Proteome Res. 8, 1368–1379 (2009).
Kobold, S., Luetkens, T., Cao, Y., Bokemeyer, C. & Atanackovic, D. Prognostic and diagnostic value of spontaneous tumor-related antibodies. Clin. Dev. Immunol. 721531 (2010).
Casal, J. I. & Barderas, R. Identification of cancer autoantigens in serum: toward diagnostic/prognostic testing? Mol. Diagn. Ther. 14, 149–154 (2010).
Leidinger, P. et al. Identification of lung cancer with high sensitivity and specificity by blood testing. Respir. Res. 11, 18 (2010).
Gnjatic, S. et al. Seromic profiling of ovarian and pancreatic cancer. Proc. Natl Acad. Sci. USA 107, 5088–5093 (2010).
Babel, I. et al. Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol. Cell. Proteomics 8, 2382–2395 (2009).
Babel, I. et al. Identification of MST1/STK4 and SULF1 proteins as autoantibody targets for the diagnosis of colorectal cancer by using phage microarrays. Mol. Cell. Proteomics 10, M110.001784 (2011).
De Bock, M. et al. Challenges for biomarker discovery in body fluids using SELDI-TOF MS. J. Biomed. Biotechnol. 2010, 9606082 (2010).
Adam, B. L. et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62, 3609–3614 (2002).
Petricoin, E. F. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572–575 (2002).
Li, J., Zhang, Z., Rosenzweig, J., Wang, Y. Y. & Chan, D. W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48, 1296–1304 (2002).
Honda, K. et al. Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res. 65, 10613–10622 (2005).
McHugh, S. M., O'Donnell, J. & Gillen, P. Genomic and oncoproteomic advances in detection and treatment of colorectal cancer. World J. Surg. Oncol. 7, 36 (2009).
Huijbers, A. et al. Proteomic serum biomarkers and their potential application in cancer Screening Programs. Int. J. Mol. Sci. 11, 4175–4193 (2010).
Engwegen, J. Y. et al. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J. Gastroenterol. 12, 1536–1544 (2006).
Wang, Q. et al. Limitations in SELDI-TOF MS whole serum proteomic profiling with IMAC surface to specifically detect colorectal cancer. BMC Cancer 9, 287 (2009).
De Noo, M. E. et al. Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur. J. Cancer 42, 1068–1076 (2006).
Ward, D. G. et al. Proteomic profiling of urine for the detection of colon cancer. Proteome Sci. 6, 19 (2008).
Smith, F. M. et al. Combination of SELDI-TOF MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann. Surg. 245, 259–266 (2007).
Liao, C. C. et al. Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry: a pilot methodological study. World J. Surg. Oncol. 8, 33 (2010).
Petricoin, E. F., Belluco, C., Araujo, R. P. & Liotta, L. A. The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat. Rev. Cancer 6, 961–967 (2006).
Albrethsen, J. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin. Chem. 53, 852–858 (2007).
Karsan, A. et al. Analytical and pre-analytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin. Chem. 51, 1525–1528 (2005).
Omenn, G. S., Aebersold, R. & Paik, Y. K. 7(th) HUPO World Congress of Proteomics: launching the second phase of the HUPOPlasma Proteome Project (PPP-2) 16–20 August 2008, Amsterdam, The Netherlands. Proteomics 9, 4–6 (2009).
Vogel, C. & Marcotte, E. M. Absolute abundance for the masses. Nat. Biotechnol. 27, 825–826 (2009).
Whiteaker, J. R. et al. A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat. Biotechnol. 29, 625–634 (2011).
Fan, R. et al. Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood. Nat. Biotechnol. 26, 1373–1378 (2008).
Rissin, D. M. et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 28, 595–599 (2010).
Gaster, R. S. et al. Matrix-insensitive protein assays push the limits of biosensors in medicine. Nat. Med. 15, 1327–1332 (2009).
Fleischhacker, M. & Schmidt, B. Circulating nucleic acids (CNAs) and cancer—a survey. Biochim. Biophys. Acta 1775, 181–232 (2007).
Vlassov, V. V., Laktionov, P. P. & Rykova, E. Y. Circulating nucleic acids as a potential source for cancer biomarkers. Curr. Mol. Med. 10, 142–165 (2010).
Schwarzenbach, H., Hoon, D. S. & Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11, 426–437 (2011).
Diehl, F. et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14, 985–990 (2008).
Leary, R. J. et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci. Transl. Med. 2, 20ra14 (2010).
He, Y. et al. Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature 464, 610–614 (2010).
Holdhoff, M., Schmidt, K., Donehower, R. & Diaz, L. A. Jr. Analysis of circulating tumor DNA to confirm somatic KRAS mutations. J. Natl Cancer Inst. 101, 1284–1285 (2009).
Lofton-Day, C. et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem. 54, 414–423 (2008).
deVos, T. et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem. 55, 1337–1346 (2009).
Mullard, A. Epigenomic colon cancer kit. Nat. Biotechnol. 27, 1066 (2009).
Tänzer, M. et al. Performance of epigenetic markers, SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS ONE 5, e9061 (2010).
Liew, C. C., Ma, J., Tang, H. C., Zheng, R. & Dempsey, A. A. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J. Lab. Clin. Med. 147, 126–132 (2006).
Han, M. et al. Novel blood-based five gene biomarker set for the detection of colorectal cancer. Clin. Cancer Res. 14, 455–460 (2008).
Marshall, K. W. et al. A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int. J. Cancer 126, 1177–1186 (2010).
Yip, K. T. et al. A case-controlled validation study of a blood-based seven-gene biomarker panel for colorectal cancer in Malaysia. J. Exp. Clin. Cancer Res. 29, 128 (2010).
Song, B. & Ju, J. Impact of miRNAs in gastrointestinal cancer diagnosis and prognosis. Expert Rev. Mol. Med. 12, e33 (2010).
Dong, Y. et al. MicroRNA dysregulation in colorectal cancer: a clinical perspective. Br. J. Cancer 104, 893–898 (2011).
Aslam, M. I., Taylor, K., Pringle, J. H. & Jameson, J. S. MicroRNAs are novel biomarkers for colorectal cancer. Br. J. Surg. 96, 702–710 (2009).
Mostert, B., Sieuwerts, A. M., Martens, J. W. & Sleijer, S. Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Rev. Mol. Diagn. 11, 259–275 (2011).
Tsujiura, M. et al. Circulating microRNAs in plasma of patients with gastric cancers. Br. J. Cancer 102, 1174–1179 (2010).
Huang, Z. et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer 127, 118–126 (2010).
Ng, E. K. et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58, 1375–1381 (2009).
Link, A. et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol. Biomarkers Prev. 19, 1766–1774 (2010).
Diamandis, E. P. Cancer biomarkers: can we turn recent failures into success? J. Natl Cancer Inst. 102, 1462–1467 (2010).
Hanash, S. M., Baik, C. S. & Kallioniemi, O. Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer. Nat. Rev. Clin. Oncol. 8, 142–150 (2011).
European Commission. European guidelines for quality assurance in colorectal cancer screening and diagnosis 1st edition. UEGF [online], (2010).
American Cancer Society. American Cancer Society recommendations for colorectal cancer early detection (People at increased or high risk). American Cancer Society [online], (2011).
Pignone, M., Rich, M., Teutsch, S. M., Berg, A. O. & Lohr, K. N. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the US preventative services task force. Ann. Intern. Med. 137, 132–141 (2002).
Sung, J. J. et al. Screening for colorectal cancer in Chinese: comparison of fecal occult blood test, flexible sigmoidoscopy, and colonoscopy. Gastroenterology 124, 608–614 (2003).
Levi, Z. et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann. Intern. Med. 146, 244–255 (2007).
Fernandes, L. C., Kim, S. B. & Matos, D. Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma. World J. Gastroenterol. 11, 645–648 (2005).
Carpelan-Holmstrom, M. et al. Estimating the probability of cancer with several tumor markers in patients with colorectal disease. Oncology 66, 296–302 (2004).
Ahlquist, D. A. et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 119, 1219–1227 (2000).
Calistri, D. et al. Fecal multiple molecular tests to detect colorectal cancer in stool. Clin. Gastroenterol. Hepatol. 1, 377–383 (2003).
Itzkowitz, S. H. et al. Improved fecal DNA test for colorectal cancer screening. Clin. Gastroenterol. Hepatol. 5, 111–117 (2007).
Wang, J. Y. et al. Development and evaluation of a colorimetric membrane-array method for the detection of circulating tumor cells in the peripheral blood of Taiwanese patients with colorectal cancer. Int. J. Mol. Med. 17, 737–747 (2006).
Chen, Y. D., Zheng, S., Yu, J. K. & Hu, X. Artificial neural networks analysis of surface enhanced laser desorption/ionisation mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin. Cancer Res. 10, 8380–8385 (2004).
Yu, J. K., Chen, Y. D. & Zheng, S. An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World J. Gastroenterol. 10, 3127–3131 (2004).
Ward, D. G. et al. Identification of serum biomarkers for colon cancer by proteomic analysis. Br. J. Cancer 94, 1898–1905 (2006).
Chen, Y. D., Xie, P. P., Yu, J. W., Zhou, J. & Zheng, S. Classification and diagnostic prediction of colorectal cancer using protein profiling of serum and bioinformatics [Chinese]. Zhejiang Da Xue Xue Bao Yi Xue Ban 38, 470–477 (2009).
Alexandrov, T. et al. Biomarker discovery in MALDI-TOF serum protein profiles using discrete wavelet transformation. Bioinformatics 25, 643–649 (2009).
Grutzmann, R. et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS ONE 3, e3759 (2008).
Wang, J. Y. et al. Molecular detection of APC, K-ras and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. World J. Surg. 28, 721–726 (2004).
Leung, W. K. et al. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am. J. Gastroenterol. 100, 2274–2279 (2005).
Schiedeck, T. H., Wellm, C., Roblick, U. J., Broll, R. & Bruch, H. P. Diagnosis and monitoring of colorectal cancer by L6 blood serum polymerase chain reaction is superior to carcinoembryonic antigen-enzyme-linked immunosorbent assay. Dis. Colon Rectum 46, 818–825 (2003).
Ng, E. K. et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58, 1375–1381 (2009).
Author information
Authors and Affiliations
Contributions
N. Pawa and J. D. Norton contributed to the research, discussion, writing and editing of this manuscript. T. Arulampalam contributed to the discussion of content and editing.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Pawa, N., Arulampalam, T. & Norton, J. Screening for colorectal cancer: established and emerging modalities. Nat Rev Gastroenterol Hepatol 8, 711–722 (2011). https://doi.org/10.1038/nrgastro.2011.205
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2011.205
This article is cited by
-
Association between preoperative anemia and postoperative short-term outcomes in patients undergoing colorectal cancer surgery - a propensity score matched retrospective cohort study
BMC Anesthesiology (2023)
-
Combined detection of SDC2/ADHFE1/PPP2R5C methylation in stool DNA for colorectal cancer screening
Journal of Cancer Research and Clinical Oncology (2023)
-
Modular and mechanistic changes across stages of colorectal cancer
BMC Cancer (2022)
-
Circ_0101802 Facilitates Colorectal Cancer Progression Depending on the Regulation of miR-665/DVL3 Signaling
Biochemical Genetics (2022)
-
A comparative examination of colorectal cancer burden in European Union, 1990–2019: Estimates from Global Burden of Disease 2019 Study
International Journal of Clinical Oncology (2022)